Ramer Robert, Hinz Burkhard
Institute of Toxicology and Pharmacology, University of Rostock, Schillingallee 70, Rostock D-18057, Germany.
J Natl Cancer Inst. 2008 Jan 2;100(1):59-69. doi: 10.1093/jnci/djm268. Epub 2007 Dec 25.
Cannabinoids, in addition to having palliative benefits in cancer therapy, have been associated with anticarcinogenic effects. Although the antiproliferative activities of cannabinoids have been intensively investigated, little is known about their effects on tumor invasion.
Matrigel-coated and uncoated Boyden chambers were used to quantify invasiveness and migration, respectively, of human cervical cancer (HeLa) cells that had been treated with cannabinoids (the stable anandamide analog R(+)-methanandamide [MA] and the phytocannabinoid delta9-tetrahydrocannabinol [THC]) in the presence or absence of antagonists of the CB1 or CB2 cannabinoid receptors or of transient receptor potential vanilloid 1 (TRPV1) or inhibitors of p38 or p42/44 mitogen-activated protein kinase (MAPK) pathways. Reverse transcriptase-polymerase chain reaction (RT-PCR) and immunoblotting were used to assess the influence of cannabinoids on the expression of matrix metalloproteinases (MMPs) and endogenous tissue inhibitors of MMPs (TIMPs). The role of TIMP-1 in the anti-invasive action of cannabinoids was analyzed by transfecting HeLa, human cervical carcinoma (C33A), or human lung carcinoma cells (A549) cells with siRNA targeting TIMP-1. All statistical tests were two-sided.
Without modifying migration, MA and THC caused a time- and concentration-dependent suppression of HeLa cell invasion through Matrigel that was accompanied by increased expression of TIMP-1. At the lowest concentrations tested, MA (0.1 microM) and THC (0.01 microM) led to a decrease in invasion (normalized to that observed with vehicle-treated cells) of 61.5% (95% CI = 38.7% to 84.3%, P < .001) and 68.1% (95% CI = 31.5% to 104.8%, P = .0039), respectively. The stimulation of TIMP-1 expression and suppression of cell invasion were reversed by pretreatment of cells with antagonists to CB1 or CB2 receptors, with inhibitors of MAPKs, or, in the case of MA, with an antagonist to TRPV1. Knockdown of cannabinoid-induced TIMP-1 expression by siRNA led to a reversal of the cannabinoid-elicited decrease in tumor cell invasiveness in HeLa, A549, and C33A cells.
Increased expression of TIMP-1 mediates an anti-invasive effect of cannabinoids. Cannabinoids may therefore offer a therapeutic option in the treatment of highly invasive cancers.
大麻素除了在癌症治疗中具有姑息作用外,还与抗癌作用有关。尽管对大麻素的抗增殖活性进行了深入研究,但对其对肿瘤侵袭的影响知之甚少。
使用基质胶包被和未包被的博伊登小室分别定量大麻素(稳定的花生四烯乙醇胺类似物R(+)-甲烷花生四烯乙醇胺[MA]和植物大麻素δ9-四氢大麻酚[THC])处理的人宫颈癌(HeLa)细胞在存在或不存在CB1或CB2大麻素受体拮抗剂、瞬时受体电位香草酸受体1(TRPV1)拮抗剂或p38或p42/44丝裂原活化蛋白激酶(MAPK)途径抑制剂的情况下的侵袭性和迁移能力。逆转录聚合酶链反应(RT-PCR)和免疫印迹用于评估大麻素对基质金属蛋白酶(MMPs)和内源性MMP组织抑制剂(TIMPs)表达的影响。通过用靶向TIMP-1的小干扰RNA(siRNA)转染HeLa、人宫颈癌(C33A)或人肺癌细胞(A549)来分析TIMP-1在大麻素抗侵袭作用中的作用。所有统计检验均为双侧检验。
MA和THC在不改变迁移能力的情况下,导致HeLa细胞通过基质胶的侵袭呈时间和浓度依赖性抑制,同时TIMP-1表达增加。在测试的最低浓度下,MA(0.1微摩尔)和THC(0.01微摩尔)导致侵袭减少(相对于用溶剂处理的细胞),分别为61.5%(95%置信区间=38.7%至84.3%,P<.001)和68.1%(95%置信区间=31.5%至104.8%,P=.0039)。用CB1或CB2受体拮抗剂、MAPK抑制剂或(对于MA)用TRPV1拮抗剂预处理细胞可逆转TIMP-1表达的刺激和细胞侵袭的抑制。用siRNA敲低大麻素诱导的TIMP-1表达导致HeLa、A549和C33A细胞中大麻素引起的肿瘤细胞侵袭性降低的逆转。
TIMP-1表达增加介导了大麻素的抗侵袭作用。因此,大麻素可能为高侵袭性癌症的治疗提供一种治疗选择。